Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH(R) for the Treatment of Common Warts
(NasdaqGM:VRCA), – Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH(R) (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the […]